CLDN4 and Alzheimer disease: The next step would be to examine astrocytic CLDN4 expression in other pathologies of the CNS, notably Alzheimer’s disease, stroke, or amyotrophic lateral sclerosis in which BBB permeability has been identified as a critical pathophysiological player.